Abstract and Introduction
Abstract
Purpose of review The management of inflammatory arthritis has been revolutionized by the use of biologic therapy. However, an important safety issue has been identified with regard to the risk of serious and opportunistic infections with biologic therapy. This review aims to summarize the most recent data available in the field.
Recent findings The risk of infection in inflammatory arthritis is partly determined by the nature of the underlying disease, comorbidities and other immunosuppressive treatments, in particular glucocorticoids. Data are conflicting with regard to the absolute risk of infection with biologic agents, as a result of differing study methodologies, classification of outcomes and patient populations. There appear to be some differences in risk of infection between biologic agents, which relate to their varying modes of action.
Summary Long-term observational data about the risk of infection and biologic therapy continue to emerge, although there are inherent limitations with this type of data. The process of determining the risk of infection for an individual patient should incorporate a range of factors, which may contribute to the infection risk.
Introduction
The treatment of rheumatic diseases has been revolutionized by the introduction of biologic drugs. An expanding list of biologic drugs is now in use in clinical practice. These agents, which are immunosuppressive or immunomodulatory, have been reported to have an association with serious or opportunistic infection, in particular tuberculosis (TB). However, the interpretation of this association is confounded by the use of other immunosuppressive drugs as well as the risk of infection related to the underlying disease. The purpose of this review is to summarize the current understanding of infection risk in relation to biologic therapy in inflammatory arthritis.
Curr Opin Rheumatol. 2014;26(4):404-409. © 2014 Lippincott Williams & Wilkins
